+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States



Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States



Clinical Therapeutics 27(6): 940-950



The aim of this study was to investigate the health-economic impact of maintaining glycosylated hemoglobin (HbA(1c)) values in all US patients with currently uncontrolled type 1 or type 2 diabetes mellitus at the American Diabetes Association (ADA) standard of 7.0% and the American Association of Clinical Endocrinologists (AACE) target of 6.5% compared with maintenance at current population-based values. The CORE-Center for Outcomes Research Diabetes Model was used to predict costs and outcomes for patients with uncontrolled type 1 and type 2 diabetes who remain at established population mean HbA(1c) values in comparison with those for patients who maintain the standard value of 7.0% or the target value of 6.5%. The analysis was run from a societal perspective over a 10-year time horizon. The costs of treating complications and medication costs were retrieved from published sources. Costs and clinical outcomes were discounted at 3% per annum. Sensitivity analyses were performed on the discount rate and time horizon. This analysis found that maintaining HbA(1c) at the ADA standard value of 7.0% and the AACE target value of 6.5% in patients with uncontrolled type 1 and type 2 diabetes could achieve total direct medical cost savings of nearly 35 US dollars and 50 billion US dollars , respectively, over 10 years. When indirect cost savings were included, the total savings increased to between nearly 50 billion US dollars and 72 billion US dollars for these respective HbA(1c) targets, corresponding to 4% and 6% of the total annual US health care costs of 1.3 trillion US dollars. Reduced savings were observed with a higher discount rate and shorter time horizon, but savings increased as the time horizon became longer. These cost savings must be weighed against the cost of reaching the HbA(1c) goals and the likelihood of achieving the clinical objectives. Efficient targeting of financial resources toward the goal of lowering HbA(1c) in line with published guidelines could lead to financial savings in the range from nearly 35 billion US dollars to 72 billion US dollars over the next 10 years.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012708484

Download citation: RISBibTeXText

PMID: 16117994

DOI: 10.1016/j.clinthera.2005.06.006


Related references

Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. Current Medical Research and Opinion 33(2): 231-238, 2016

Impact of smoking cessation on estimated cardiovascular risk in Spanish type 2 diabetes mellitus patients: The DIABETES study. Revista Clinica Espanola 218(8): 391-398, 2018

Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). European Journal of Medical Research 9(8): 391-399, 2004

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clinical Therapeutics 28(10): 1712-25; Discussion 1710-1, 2006

Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. Journal of Medical Economics 18(6): 420-432, 2016

Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Therapy 5(2): 579-590, 2014

AGE-products N-epsilon-Carboxymethyllysine and pentosidine in patients with type 1 and insulin-treated type 2 diabetes mellitus Results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany. Diabetologia 45(Supplement 2): A 355-A 356, 2002

Pancreas Transplantation for Patients with Type 1 and Type 2 Diabetes Mellitus in the United States: A Registry Report. Gastroenterology Clinics of North America 47(2): 417-441, 2018

The quality of life of patients with type 1 and type 2 diabetes mellitus and impact on quality of diabetes care JEVIN, a population-based survey. Diabetologia 44(Supplement 1): A258, 2001

Impact of diabetes education and self-management on the quality of care for people with type 1 diabetes mellitus in the Middle East (the International Diabetes Mellitus Practices Study, IDMPS). Diabetes Research and Clinical Practice 147: 29-36, 2018

Economic considerations in treating patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy 59 Suppl 9: S14-S17, 2002

A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clinical Therapeutics 32(7): 1308-1319, 2010

Comparison of the Economic Burden and Health care Utilizations of u. S. Veteran Patients Diagnosed with Type 2 Diabetes Mellitus. Value in Health 17(7): A341, 2014

Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus. Pediatric Diabetes 12(8): 724-732, 2012

Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 9(4): 776-781, 2017